These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 19689330)

  • 1. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.
    Stone JM
    Curr Pharm Des; 2009; 15(22):2594-602. PubMed ID: 19689330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.
    Poels EM; Kegeles LS; Kantrowitz JT; Slifstein M; Javitt DC; Lieberman JA; Abi-Dargham A; Girgis RR
    Mol Psychiatry; 2014 Jan; 19(1):20-9. PubMed ID: 24166406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of Molecular Imaging of Glutamate Receptors.
    Kim JH; Marton J; Ametamey SM; Cumming P
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between
    Beck K; Arumuham A; Brugger S; McCutcheon RA; Veronese M; Santangelo B; McGinnity CJ; Dunn J; Kaar S; Singh N; Pillinger T; Borgan F; Sementa T; Neji R; Jauhar S; Aigbirhio F; Boros I; Turkheimer F; Hammers A; Lythgoe D; Stone J; Howes OD
    J Psychopharmacol; 2022 Sep; 36(9):1051-1060. PubMed ID: 36120998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia.
    Okubo R; Okada M; Motomura E
    Biomolecules; 2024 Sep; 14(9):. PubMed ID: 39334894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic Resonance Spectroscopy in Schizophrenia: Evidence for Glutamatergic Dysfunction and Impaired Energy Metabolism.
    Duarte JMN; Xin L
    Neurochem Res; 2019 Jan; 44(1):102-116. PubMed ID: 29616444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.
    Bustillo JR; Chen H; Jones T; Lemke N; Abbott C; Qualls C; Canive J; Gasparovic C
    JAMA Psychiatry; 2014 Mar; 71(3):265-72. PubMed ID: 24402128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial.
    Javitt DC; Carter CS; Krystal JH; Kantrowitz JT; Girgis RR; Kegeles LS; Ragland JD; Maddock RJ; Lesh TA; Tanase C; Corlett PR; Rothman DL; Mason G; Qiu M; Robinson J; Potter WZ; Carlson M; Wall MM; Choo TH; Grinband J; Lieberman JA
    JAMA Psychiatry; 2018 Jan; 75(1):11-19. PubMed ID: 29167877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamatergic aspects of schizophrenia.
    Tamminga C
    Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time-Averaged Proton Magnetic Resonance Spectroscopy at 4T.
    Kim SY; Kaufman MJ; Cohen BM; Jensen JE; Coyle JT; Du F; Öngür D
    Biol Psychiatry; 2018 Mar; 83(6):484-491. PubMed ID: 29031411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glutamate hypothesis of schizophrenia: neuroimaging and drug development.
    Egerton A; Stone JM
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1500-12. PubMed ID: 22283750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using proton magnetic resonance spectroscopic imaging to study glutamatergic alterations in patients with schizophrenia: A systematic review.
    Plitman E; Guma E; Lepage M; Near J; Chakravarty MM
    Schizophr Res; 2019 Aug; 210():13-20. PubMed ID: 31272905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 7T Proton Magnetic Resonance Spectroscopy of Gamma-Aminobutyric Acid, Glutamate, and Glutamine Reveals Altered Concentrations in Patients With Schizophrenia and Healthy Siblings.
    Thakkar KN; Rösler L; Wijnen JP; Boer VO; Klomp DW; Cahn W; Kahn RS; Neggers SF
    Biol Psychiatry; 2017 Mar; 81(6):525-535. PubMed ID: 27316853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.
    Poels EM; Kegeles LS; Kantrowitz JT; Javitt DC; Lieberman JA; Abi-Dargham A; Girgis RR
    Schizophr Res; 2014 Feb; 152(2-3):325-32. PubMed ID: 24418122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging the glutamatergic system in vivo--relevance to schizophrenia.
    Bressan RA; Pilowsky LS
    Eur J Nucl Med; 2000 Nov; 27(11):1723-31. PubMed ID: 11105831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation.
    Salavati B; Rajji TK; Price R; Sun Y; Graff-Guerrero A; Daskalakis ZJ
    Schizophr Bull; 2015 Jan; 41(1):44-56. PubMed ID: 25249654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The acute effects of NMDA antagonism: from the rodent to the human brain.
    Gunduz-Bruce H
    Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.